Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
Launched by ASTRAZENECA · Jul 11, 2011
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes mellitus
- • Men or women age ≥ 18 years old
- • Stable dose combination of metformin and sulfonylurea
- • HbA1c ≥7.7% and ≤11.0%
- Exclusion Criteria:
- • Type 1 diabetes mellitus or diabetes insipidus
- • Recent cardiovascular events
- • Kidney or urological disorders
- • Hepatic disorders
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Halifax, Nova Scotia, Canada
Praha, , Czech Republic
Berlin, , Germany
Quebec, , Canada
Kielce, , Poland
Lodz, , Poland
Lublin, , Poland
Warszawa, , Poland
Winnipeg, Manitoba, Canada
St. John's, Newfoundland And Labrador, Canada
Barcelona, Cataluna, Spain
Laval, Quebec, Canada
Markham, Ontario, Canada
Poznan, , Poland
Praha 6, , Czech Republic
Oviedo, Asturias, Spain
Ceske Budejovice, , Czech Republic
Kosice, , Slovakia
Dresden, , Germany
Banska Bystrica, , Slovakia
Beroun, , Czech Republic
Praha 5, , Czech Republic
Brampton, Ontario, Canada
Etobicoke, Ontario, Canada
Pirna, , Germany
Semily, , Czech Republic
Poznań, , Poland
Povazska Bystrica, , Slovakia
Neuwied, , Germany
A Coruña, , Spain
łódź, , Poland
Rimavska Sobota, , Slovakia
Falkensee, , Germany
A Coruna, Galicia, Spain
Asslar, , Germany
Sydney Mines, Nova Scotia, Canada
Kensington, , Canada
Smiths Falls, Ontario, Canada
Zgierz, , Poland
Vyskov, , Czech Republic
Jilove U Prahy, , Czech Republic
Aßlar, , Germany
Sta Coloma De Gramanet (Bcn), Catalu?A, Spain
Sta Coloma De Gramenet (Bcn), , Spain
Kensington, Prince Edward Island, Canada
Sta Coloma De Gramanet (Bcn), , Spain
Patients applied
Trial Officials
Eva Johnsson, PhD, Medical Science Director
Study Director
AstraZeneca R&D, Global Medicines Development CVGI, SE-431 83 Mölndal, Sweden
Stephan Matthaei, Prof.Dr.med
Principal Investigator
Diabetes-Zentrum Quakenbruck
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials